While these findings underscore the feasibility and potential efficacy of anti-CD19 CAR-T cells in pediatric SLE, further research is essential to optimize dosing strategies, evaluate long-term safety, and address developmental and immunologic considerations unique to the pediatric population. Here, CD19 is linked to systemic lupus erythematosus.